TSHR Inhibitors
1 drugsAbout TSHR
TSHR (Thyrotropin Receptor) is a GPCR primarily regulating thyroid hormone synthesis and secretion. Its activation modulates cellular signaling pathways, extending its relevance beyond thyroid disorders. TSHR is being explored in oncology.
TSHR's therapeutic potential lies in modulating cellular signaling pathways. Currently, there is no genetic evidence available linking TSHR to specific diseases. Drugs targeting TSHR could offer novel therapeutic strategies.
TSHR is targeted by one FDA-approved drug, THYROGEN (Sanofi), a biologic used in oncology. THYROGEN was first approved in 1998 and remains the only approved drug.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Thyroid Cancer with only 1 trials.
Top Drugs
Sanofi is the only company with an approved TSHR-targeting drug.
Low competition suggests a high barrier to entry or untapped market potential for new entrants.
Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets TSHR, using enzyme modality.
The lack of modality diversity suggests an opportunity for small molecule or antibody-based TSHR therapeutics.
Clinical Trials 19 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 9 | 8 | 0 | 1 | 100% |
| Phase 2 | 3 | 1 | 0 | 2 | 100% |
| Phase 3 | 4 | 4 | 0 | 0 | 100% |
| Phase 4 | 3 | 2 | 1 | 0 | 67% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Drug Approval Timeline (1998 - 1998)
THYROGEN was approved in 1998 and no new drugs have been approved since.
The stagnant approval timeline indicates a saturated market or challenges in developing new TSHR-targeting drugs.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (11 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 11 clinical trials targeting TSHR.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities